MGX
Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. insider trading
Metagenomi Therapeutics, Inc. is on this site because an insider bought its stock on the open market in the last 30 days. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
From SEC filings · last 30 days
Recent MGX insider transactions
The filing store could not be read just now — this page tries again on its next refresh. The filings themselves are on SEC EDGAR.
SEC Form 4 data, Q3 2024 to Q2 2026
MGX insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 5 insiders traded MGX on the open market: 0 purchases and 23 sales worth $107.4K. In the last four quarters alone: 0 purchases and 14 sales ($39K), by 4 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | −$9.3K3 sales | |
| Q1 2026 | — | −$5.9K3 sales | |
| Q4 2025 | — | −$12.8K4 sales | |
| Q3 2025 | — | −$11K4 sales | |
| Q2 2025 | — | −$42.3K5 sales | |
| Q1 2025 | — | −$5.1K2 sales | |
| Q4 2024 | — | −$2.9K1 sale | |
| Q3 2024 | — | −$18K1 sale |
- Largest sale
- −$18.9K of MGX by Thomas Brian C. (Chief Executive Officer · Director) on Jun 06, 2025.
Open-market transactions through Jun 30, 2026most recent first
Irish Jian
President and Chief Executive Officer · Director
−$4.9K
Jun 05, 2026
3,737 sh · $1.30
Wapnick Pamela
Chief Financial Officer
−$3.7K
Jun 05, 2026
2,884 sh · $1.30
Wein Matthew
Officer
−$725
Jun 05, 2026
558 sh · $1.30
Irish Jian
Chief Executive Officer · Director
−$2.6K
Mar 05, 2026
1,607 sh · $1.60
Wapnick Pamela
Chief Financial Officer
−$2.5K
Mar 05, 2026
1,581 sh · $1.60
Wein Matthew
Officer
−$771
Mar 05, 2026
482 sh · $1.60
Thomas Brian C.
Director
−$6.8K
Dec 05, 2025
3,830 sh · $1.77
Irish Jian
Chief Executive Officer · Director
−$2.8K
Dec 05, 2025
1,602 sh · $1.77
Wapnick Pamela
Chief Financial Officer
−$2.8K
Dec 05, 2025
1,576 sh · $1.77
Wein Matthew
Officer
−$352
Dec 05, 2025
199 sh · $1.77
Thomas Brian C.
Director
−$4.9K
Sep 05, 2025
2,701 sh · $1.81
Irish Jian
Chief Executive Officer · Director
−$2.9K
Sep 05, 2025
1,602 sh · $1.81
Wapnick Pamela
Chief Financial Officer
−$2.9K
Sep 05, 2025
1,576 sh · $1.81
Wein Matthew
Officer
−$360
Sep 05, 2025
199 sh · $1.81
Thomas Brian C.
Chief Executive Officer · Director
−$18.9K
Jun 06, 2025
10,785 sh · $1.75
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Jun 05, 2026 | Irish JianPresident and Chief Executive Officer · Director | 3,737 | $1.30 | −$4.9K |
| Jun 05, 2026 | Wapnick PamelaChief Financial Officer | 2,884 | $1.30 | −$3.7K |
| Jun 05, 2026 | Wein MatthewOfficer | 558 | $1.30 | −$725 |
| Mar 05, 2026 | Irish JianChief Executive Officer · Director | 1,607 | $1.60 | −$2.6K |
| Mar 05, 2026 | Wapnick PamelaChief Financial Officer | 1,581 | $1.60 | −$2.5K |
| Mar 05, 2026 | Wein MatthewOfficer | 482 | $1.60 | −$771 |
| Dec 05, 2025 | Thomas Brian C.Director | 3,830 | $1.77 | −$6.8K |
| Dec 05, 2025 | Irish JianChief Executive Officer · Director | 1,602 | $1.77 | −$2.8K |
| Dec 05, 2025 | Wapnick PamelaChief Financial Officer | 1,576 | $1.77 | −$2.8K |
| Dec 05, 2025 | Wein MatthewOfficer | 199 | $1.77 | −$352 |
| Sep 05, 2025 | Thomas Brian C.Director | 2,701 | $1.81 | −$4.9K |
| Sep 05, 2025 | Irish JianChief Executive Officer · Director | 1,602 | $1.81 | −$2.9K |
| Sep 05, 2025 | Wapnick PamelaChief Financial Officer | 1,576 | $1.81 | −$2.9K |
| Sep 05, 2025 | Wein MatthewOfficer | 199 | $1.81 | −$360 |
| Jun 06, 2025 | Thomas Brian C.Chief Executive Officer · Director | 10,785 | $1.75 | −$18.9K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check MGX — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Metagenomi Therapeutics, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- How much MGX stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 5 Metagenomi Therapeutics, Inc. insiders made no open-market purchases and 23 sales worth $107.4K. In the four quarters to Jun 30, 2026: no purchases and 14 sales ($39K). The largest sale was Thomas Brian C. selling $18.9K on Jun 06, 2025.
- Where does MGX insider trading data come from?
- From the Form 4 filings Metagenomi Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.